You are here

Cancer Cell DOI:10.1016/j.ccr.2006.09.006

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.

Publication TypeJournal Article
Year of Publication2006
AuthorsWei, G, Twomey, D, Lamb, J, Schlis, K, Agarwal, J, Stam, RW, Opferman, JT, Sallan, SE, Boer, ML den, Pieters, R, Golub, TR, Armstrong, SA
JournalCancer Cell
Date Published2006 Oct
KeywordsAnimals, Cell Line, Tumor, Cell Survival, Databases, Genetic, Dexamethasone, Dose-Response Relationship, Drug, Drug Combinations, Drug Resistance, Neoplasm, Gene Expression, Genomics, Glucocorticoids, Green Fluorescent Proteins, Humans, Mice, Myeloid Cell Leukemia Sequence 1 Protein, Neoplasm Proteins, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Proto-Oncogene Proteins c-bcl-2, Sirolimus

Drug resistance remains a major obstacle to successful cancer treatment. A database of drug-associated gene expression profiles was screened for molecules whose profile overlapped with a gene expression signature of glucocorticoid (GC) sensitivity/resistance in acute lymphoblastic leukemia (ALL) cells. The screen indicated that the mTOR inhibitor rapamycin profile matched the signature of GC sensitivity. We tested the hypothesis that rapamycin would induce GC sensitivity in lymphoid malignancy cells and found that it sensitized to GC-induced apoptosis via modulation of antiapoptotic MCL1. These data indicate that MCL1 is an important regulator of GC-induced apoptosis and that the combination of rapamycin and glucocorticoids has potential utility in lymphoid malignancies. Furthermore, this approach represents a strategy for identification of promising combination therapies for cancer.


Alternate JournalCancer Cell
PubMed ID17010674
Grant ListK08 CA92551 / CA / NCI NIH HHS / United States
P01 CA068484 / CA / NCI NIH HHS / United States